Johnson & Johnson has gained an EU approval for Akeega, a new combination therapy for use in first-line metastatic castration-resistant prostate cancer (mCRPC), but with a label that is more restricted than its key rival, stymieing its commercial prospects.
Akeega is a fixed-dose combination of GSK’s PARP inhibitor Zejula (niraparib) and J&J’s prostate cancer treatment Zytiga (abiraterone acetate),...